GlassScriptPhysician profile
Kristen E Drew
NPI 1720718968
$3,491.20
in general payments reported to CMS, 2019-2025
22 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $313 · 2024: $1,294 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,407 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,407.20 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.15 | 2023-2025 | |
| Janssen Biotech, INC. | $444.92 | 2024-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $340.63 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $218.98 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $208.21 | 2024-2025 | Entyvio |
| Genzyme Corporation | $168.80 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $145.35 | 2025 | Iqirvo |
| Enterra Medical, INC. | $145.14 | 2025 | |
| Ardelyx, INC. | $137.84 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $125.00 | 2025 | Livdelzi |
| E.R. Squibb & Sons, L.L.C. | $121.12 | 2024 | Zeposia |
| Novo Nordisk INC | $106.15 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.57 | 2024 | Xifaxan |
| Pfizer INC. | $49.88 | 2023-2025 | |
| Qol Medical, LLC | $45.85 | 2025 | Sucraid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $41.43 | 2024 | Dupixent |
| Celgene Corporation | $30.59 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $22.49 | 2025 | |
| Ironwood Pharmaceuticals, INC | $20.98 | 2023 | Linzess |
| Lilly USA, LLC | $18.39 | 2025 | Omvoh |
| Nestle Healthcare Nutrition INC. | $17.09 | 2023 | |
| Aimmune Therapeutics, INC. | $14.64 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Drew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.